I am an early career scientific researcher who has taken a strong interest in investing, both for achieving my personal financial goals as well as serving as an alternative conduit where critical and logical thinking are appreciated and rewarded. I write articles to share ideas, refine my own thinking and invite discussion from the astute readership of Seeking Alpha.
For a better Seeking Alpha experience on your phone, please consider viewing the website on your browser (request desktop site for full functionality) instead of through the Seeking Alpha app.
Within the academic field, I have a career total of 87 articles and 5 book chapters, 2,600 total citations and an h-index of 31 (metrics from Google Scholar).
Spencer Osborne is founder of Satellite Standard Group [SSG], and a partner of Sirius Buzz (http://siriusbuzz.com/). Sirius Buzz covers the satellite radio industry as well as companies that do business in this sector. Sirius Buzz provides information and opinion to readers with an interest in the sector from an investment, as well as consumer perspective.
Along with his work in the media sector, Spencer covers various equities that interest him and writes about these equities from a unique and "out of the box" perspective. Over the years Spencer has built a network of resources within the sectors he writes about. His opinion and insight is oft referred to and sought after by analysts.
I am now retired from the US pharma industry having spent over 33 years in the Mid-Atlantic corridor in Sales(Hospital mainly), Scientific Relations and Managed Care/LTC. I worked at BMY, Bayer/Miles Labs and SGP/MRK prior to early retirement..
Today I enjoy investing in Bio-Pharmas mostly, because it is what I know best!
I invest mostly in large companies such as BMY, PFE, MRK, GSK, and JNJ (love the divis) but I like the up and coming Bios like CLDX. Cancer and Immunotherapy intrigues me..so I have made that a major consideration since 2008....With BARDA,the GAIN act and QDIP Ive come to appreciate the Antibiotic cos.and have made them a major component of my LT strategy to build wealth while in Retirement....Ive invested in Trius(TSRX),CBST, CEMP, DRTX, TTPH, CTIX and just added AKAO.....
I manage personal monies and some family members..gratis of course!
Paul Wagner is a seasoned stock investor with a long background in financial analysis and portfolio management. His career in credit and financial analysis began in 1967 at Dun & Bradstreet while he was still attending North Park College in Chicago. After a stint in the U.S. Army he began a 25-year career with Heller Financial, a premier secured lender to middle market companies. In 1997, he left his position there as the senior credit executive of Heller's Current Asset Management Group to create and manage his own portfolios of public securities. He has written several articles for Seeking Alpha and in 2012 authored a short book on investing fundamentals for newer stock investors.
Paul's book is available here.
Simply Safe Dividends helps dividend investors increase current income, make better investment decisions, avoid risk, and grow their wealth faster.
I am a buy and hold common stock investor. Warren Buffett is definitely my guru. He makes the most sense to me. I began investing in the stock market at age 14 in 1970 with money earned on my paper route. What I have done since 1970 is invest primarily in the Dividend Aristocrats whenever the stock market is relatively low. I have never sold a single share of stock except on the rare occasion when one of my stocks was bought out for cash and I was forced to sell.. I keep all of my stock certificates or direct registration statements in a safe deposit box at the bank. I do not automatically reinvest dividends. I only purchase stocks when I feel that the stock market is relatively low. Brown University, B. A., 1978. Below are the 35 stocks in my portfolio.
The Clinically Sound Investor is a pharmacist for a large retail corporation, with a PharmD and a BA in psychology. Fascinated by watching the rise of Walmart and Apple after 2008, he now follows the advice "know thyself" and puts expertise of understaning scientific literature to research biotechnology stocks. His investments early on were driven by binary events such as FDA Advisory Committee meetings and PDUFA dates (approvals). Despite initial successes, there were too few of these events, so he expanded into predicting Phase II/III trial results.
His writings should not be considered financial advice or the basis for investment decisions. While his interpretations of clinical trial results--which may be overlooked or even thoroughly misunderstood by Wall Street--could be helpful, they're only as good as the original reports they come from. Although written by scientists and doctors, there will always be a slant from the sponsoring company, or worse (like, say, missing data...).
I worked in New York's financial sector for almost exactly 20 years, mostly as a healthcare analyst (drugs, biotech, and medical devices), but also as an assistant research director, portfolio manager, and options strategist. My last formal job had me in charge of Value Line's premium priced "Select" and "Special Situation" products. The former highlights the company's top stock pick of each month and the latter introduces relatively small companies. I quit that job in June, 2009 for reasons that a dozen or so confidentiality agreements preclude my discussing. In September of that year, I launched 3DimensionalResearch.com (3DR), which allows me to continue doing what I was doing previously.
I am a strong believer in maximum transparency, in both personal and business relationships. So, in that vein:
A google search will show that my former employer sued 3DR and me in November, 2009 for copyright infringement, hot news misappropriations, and the proverbial kitchen sink. Although a search won't show this, unfortunately, I represented myself in a federal courtroom in December and, in accordance with the judge's instructions, the case was settled in a matter of minutes.
Additional Disclosure: 3DR has been a financial failure thus far, in terms of getting subscribers. I detest marketing and few people want to pay for information anymore, least of all from a no-name website. That said, the vast majority of my recommendations have done very well and my personal portfolio is doing extraordinarily well (65.5% in 2013) since I tend to follow most of my own recommendations, the "event driven special situations," in particular.
Over 30 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
I ran the 20/20 fund from 1999 through 2005. Prior to that, I was the investment adviser for M.A. Berman Co, with assets approaching $750 million. I have been a contributor to publications including the New York Times, Thestreet.com and others. I currently manage my own investments.
Private investment analyst and writer with an interest in companies with emerging technologies oriented towards improving healthcare, alternative investments, emerging markets, and technology.
Ben S. Bernanke is a Distinguished Fellow in Residence with the Economic Studies Program at the Brookings Institution. From February 2006 through January 2014, he was Chairman of the Board of Governors of the Federal Reserve System. Dr. Bernanke also served as Chairman of the Federal Open Market Committee, the System's principal monetary policymaking body.
Before his appointment as Chairman, Dr. Bernanke was Chairman of the President's Council of Economic Advisers, from June 2005 to January 2006. He had already served the Federal Reserve System in several roles. He was a member of the Board of Governors of the Federal Reserve System from 2002 to 2005; a visiting scholar at the Federal Reserve Banks of Philadelphia (1987-89), Boston (1989-90), and New York (1990-91, 1994-96); and a member of the Academic Advisory Panel at the Federal Reserve Bank of New York (1990-2002).
From 1994 to 1996, Dr. Bernanke was the Class of 1926 Professor of Economics and Public Affairs at Princeton University. He was the Howard Harrison and Gabrielle Snyder Beck Professor of Economics and Public Affairs and Chair of the Economics Department at the university from 1996 to 2002. Dr. Bernanke had been a Professor of Economics and Public Affairs at Princeton since 1985.
Before arriving at Princeton, Dr. Bernanke was an Associate Professor of Economics (1983-85) and an Assistant Professor of Economics (1979-83) at the Graduate School of Business at Stanford University. His teaching career also included serving as a Visiting Professor of Economics at New York University (1993) and at the Massachusetts Institute of Technology (1989-90).
Dr. Bernanke has published many articles on a wide variety of economic issues, including monetary policy and macroeconomics, and he is the author of several scholarly books and two textbooks. He has held a Guggenheim Fellowship and a Sloan Fellowship, and he is a Fellow of the Econometric Society and of the American Academy of Arts and Sciences. Dr. Bernanke served as the Director of the Monetary Economics Program of the National Bureau of Economic Research (NBER) and as a member of the NBER's Business Cycle Dating Committee. In July 2001, he was appointed Editor of the American Economic Review. Dr. Bernanke's work with civic and professional groups includes having served two terms as a member of the Montgomery Township (N.J.) Board of Education.
Dr. Bernanke was born in December 1953 in Augusta, Georgia, and grew up in Dillon, South Carolina. He received a B.A. in economics in 1975 from Harvard University (summa cum laude) and a Ph.D. in economics in 1979 from the Massachusetts Institute of Technology.
Dr. Bernanke is married and has two children.
I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
Chris Faulkner, Founder, President and Chief Executive Officer Breitling Energy Corporation (BECC), is the driving force behind the company’s growth, technology innovations and strategic approach to oil and gas exploration and production.
Informally dubbed “Frack Master” in the media for his unapologetic and outspoken industry advocacy, Mr. Faulkner has received numerous industry recognitions and accolades including being named Industry Leader of the Year in 2013 by the Oil & Gas Awards for the Southwest Region, Dallas 40 Under 40 by the Dallas Business Journal 2014, Best Exploration and Production Company for North America in 2014 by World Finance, Oil Executive of the Year in 2013 by the American Energy Research Group, and recognized in the “Dallas Who’s Who in Energy” the last three consecutive years. Breitling Energy received the 2013 Aggreko Award for Excellence in Environmental Stewardship from the Oil & Gas Awards for the Gulf Coast Region, was named 2013 E&P Company of the Year by the Oil & Gas Awards for the Southwest Region, “Best North American Operator” by World Finance Magazine in 2011, 2012 and 2013, and to the “Dallas 100 List” in 2013, ranking fourth among the top 100 companies in the Dallas-Fort Worth area, and the prestigious Excellence in Social Responsibility 2014 by Oil and Gas Awards.
Mr. Faulkner brings a unique perspective to energy policy conversations in Washington, DC. While he understands the granular details of energy production–from the technical to the financial aspects—he has a global view of energy policy. He’s a trusted source of information for lawmakers on Capitol Hill, journalists and Washington policy analysts from respected think tanks. Mr. Faulkner kicked off the Natural Gas Roundtable luncheon series of 2014 in Washington and the CSIS/USAEE annual energy policy conference in Washington.
A knowledgeable and dynamic speaker whose oil and gas industry expertise is well regarded and sought after, Mr. Faulkner has been featured in hundreds of broadcast and print news outlets, including CNBC, FOX Business News, NBC News, and the Voice of America, as well as Forbes, US News & World Report, Bloomberg Businessweek, Inside Market Data, Oil and Gas Monitor, Petroleum Review, and Financial Times. He is a crowd favorite on the speaking circuit, giving dozens of keynote and other presentations at industry conferences in the U.S. and around the globe, including The Unconventional Gas and The Environment Conference in London, Shale Gas World Asia in Singapore, World Congress of Petroleum Microbiology in China, Oil Council Energy Capital Assembly in New York, and EMEA Unconventional Gas Exploration and Production in Turkey.
Mr. Faulkner is responsible for the company’s long-range economic and energy outlooks in support of investor relations, short and long-term business strategy, mergers and acquisitions, and the development and application of new and existing technology for optimizing recovery efficiency within Breitling Energy’s conventional and unconventional resources.
Mr. Faulkner serves as an advisor to the ECF Asia Shale Committee and sits on the Board of Directors for the North Texas Commission. He is also a member of the Texas Alliance of Energy Producers, the Dallas Petroleum Club, Independent Petroleum Association of America, Texas Alliance of Energy Producers and Texas Independent Producers and Royalty Owners Association. He is actively involved in local and national philanthropic and non-profit organizations, including Dallas Performing Arts, Texas CAN-DO, American Heart Association and Big Brothers Big Sisters.
Mr. Faulkner studied biomedical engineering at Southern Methodist University, business and mathematics at Baylor University and at the University of North Texas.
Ray Dalio is the Chairman and co-Chief Investment Officer of Bridgewater Associates, which is a global macro investment firm and is the world’s largest hedge fund. He is known to have a very practical understanding of economics that is very different from conventional economic thinking and that he spelled out in "How the Economic Machine Works".
He started Bridgewater in 1975 out of a two bedroom apartment in New York City and has been a global macro investor for more than 45 years.
While at Bridgewater his industry-changing approaches to investing -- which include the invention of risk parity, currency overlay, portable alpha and global inflation indexed bond management -- prompted Alternative Investment CIO to write an article entitled “Is Ray Dalio the Steve Jobs of Investing?”, which compared his industry-changing inventions to those of the Apple founder. According to an industry study, Bridgewater's hedge fund has made more money for its investors than any other hedge fund ever -- an estimated $37 billion. Bridgewater Associates has received numerous awards, including over twenty “Manager of the Year” awards from every major financial publication, and Ray has received three “Lifetime Achievement” awards. Additionally, a long list of economic policy makers actively seek his advice, which prompted Time Magazine in 2012 to name him “One of the 100 Most Influential People in the World”.
Ray is an active philanthropist with a particular interest in oceanographic research and conservation. He is a participant in The Giving Pledge, a commitment to give more than half of his wealth to charity.
Ray believes that reality works like a machine and that principles for dealing with reality are required to be successful. For those who are interested in learning the principles that led to Ray's success, he set them out in Principles.org which focuses on management principles and EconomicPrinciples.org which describes the principles of the economic machine.
Chief Investment Officer for Stanford Wealth Management, a Registered Investment Advisor. Retired senior executive of Charles Schwab. Retired (36 years) active and reserve military service -- six in special operations, 30 in the intelligence community. Geopolitical analyst. Author -- investment book Bringing Home the Gold.
Editor -- The Investor’s Edge®. In the 16 years from inception through year-end 2015, the Investor’s Edge® Growth & Value Portfolio increased in value from $250,000 to $1,038,453. That same $250,000 invested in the S&P 500 rose to just $422,905. (Past results are no guarantee of future performance; maybe those 16 years were pure luck.) SEE SPECIAL OFFER BELOW! Featured in Forbes, Barrons, The Wall Street Journal, Financial World, Wall Street Transcript, Global Investing, Welling on Wall Street, etc.
SUMMER SPECIAL: June and July ONLY, receive 1 year of Investor's Edge®, normally $189, for just $99. If you are ever not 100% satisfied, we provide a pro rata refund for any issues not yet received. Phone orders only! 775 832-5440.
5i Research is an independent, conflict-free investment research provider covering over 70 companies listed on the TSX and TSX Venture Exchange. Peter Hodson, former chairman of Sprott Asset Management, is the founder and CEO of 5i Research.
Dr. Bill Conerly connects the dots between the economy and business decisions. He has the unique combination of a Ph.D. in economics from Duke University and over 30 years’ experience helping companies adapt to changing economic conditions. He has worked in economics and corporate planning at two Fortune 500 corporations and at a major bank, where he was senior vice president. He has earned the Chartered Financial Analyst (CFA) designation.
Companies have used Dr. Conerly’s expertise to help with decisions regarding capital expenditures, inventory levels, expansion into new markets, pricing, business models and financial structure.
Dr. Conerly is an on-line contributor to Forbes.com and the author of The Flexible Stance: Thriving in a Boom/Bust Economy (2016) as well as Businomics (2007). He had been interviewed on the News Hour with Jim Lehrer, CNN and CNBC. He has been quoted in the Wall Street Journal, Fortune Magazine, and USA Today.
I focus on investments in the oil & gas sector with an eye for dividend income and long-term capital appreciation. I typically allocate a portion of my own portfolio and devote some of my Seeking Alpha articles to small and medium sized companies offering compelling risk/reward propositions.
I am an engineer, not a qualified investment advisor. While the information and data presented in this article were obtained from company documents and/or sources believed to be reliable, they have not been independently verified. Therefore, I cannot guarantee its accuracy. I advise investors conduct their own research and/or consult a qualified investment advisor. I explicitly disclaim any liability that may arise from investment decisions you make based on this article. Thanks for reading and I wish you much success – Michael Fitzsimmons.
William Koenig, CFA,CMA was formerly Chief Investment Officer of several successful fund management companies based in Canada. His focus was primarily Natural Resources and Small Cap investing. He also spent time as a research analyst for several investment banking firms prior to switching to the Buy side. With over 20 years in the industry he now runs his own commodity consulting company.
Chris Damas' contrarian equity research is broad based and covers energy production and infrastructure, metals, agriculture, chemicals, forestry, industrials, telecoms, retail, technology, financials, transports, renewables and special situations as well as US MLP's. Chris managed the second largest preferred share portfolio on Bay Street during the 80's and also follows currency and fixed income markets closely. His investment universe is broad and he spends most of his time hunting for actionable trade ideas and long term investment opportunities. His investment thinking and trading activity are now only available by subscribing to the US and Canadian versions of The BCMI Report (trademark) and The BCMI Flash (trademark) which are issued at least weekly and more frequently when opportunities and market conditions demand it.
Value Digger holds MSc. in Electrical Engineering, speaks four languages (English, French, Greek, German) and has lived in the U.S. for many years. Also, he is a full-time investor and a freelance writer with one of the highest Followers per Article (F/A) rates in Seeking Alpha. His F/A rate in Seeking Alpha is above 30.
After creating "Nathan's Bulletin" (a subscription-based investment guide for investors who can't afford a financial advisor), Value Digger launched a subscription-based Premium Service in Seeking Alpha entitled "A Fundamental Investor's Stock Club" which includes an unparalleled, actively-managed and high-return Portfolio of unknown and/or underfollowed stocks. Regularly updated and detailed lists in his Premium Posts PROVE these high returns. For reference, when Value Digger was managing money in the early 2000s, his Portfolio's annual ROI consistently exceeded 50%. His Premium Research is based on a comprehensive review of company-specific factors, macro conditions, competitors and the industry trends.
When it comes to his publicly-available picks and his free Seeking Alpha articles, Value Digger is ranked in the TOP-50 with a success rate of over 80%, an average return per recommendation of over 30% and a 5-star rating according to TipRanks.com, which is the highest category quality ranking used to evaluate financial experts. TipRanks.com is a comprehensive investing tool that allows private investors and day traders to see the measured performance of anyone who publicly provides financial advice. TipRanks.com collects data, evaluates and ranks 9,000 financial experts worldwide.
After almost 30 years of investing experience in the international markets (U.S., Canada, Australia, Europe), Value Digger has formulated a deep understanding of valuation analysis and his investment philosophy is firmly grounded in Ben Graham-style value-oriented opportunities that often have an assymetric risk/reward profile. On that front, he has created a unique proprietary database with thousands of publicly-traded companies per sector, which helps him spot the bargains and the bubbles before many investors find them.
I am a former hedge fund portfolio manager that trades for my own personal account. I espouse Graham and Dodd/Buffett style investing, always on the lookout for value equities or bonds. A graduate of Northwestern's Kellogg School of Management, I lived in NYC for a decade before relocating with my family to the Charlotte, NC area in 2007.
Currently I am the Chief Analyst at sharpeequities.com.
For more information on my current endeavor, feel free to find me on LinkedIn.
I am a Level III candidate in the CFA program. I have passed the Level I exam in June 2014 and the Level II exam in June 2015.
Outside of my interest in investing and stock analysis (which I currently do in my free time,) I am an IT project manager for a large multi-national firm. With my background in technology I have particular interest and stronger circle of competence in tech stocks, although I venture from this domain to certain other industries as well where I feel the businesses are simple and understandable or where I have particular first hand knowledge.
I consider myself a value investing enthusiast, following a bottom up fundamental analysis style approach. My value investing approach is quite simple - I look to "figure out the value of something, and pay a lot less".
I do not consider Growth and Value stocks as mutually exclusive, and in fact my favorite investments are:
small cap companies with good long term growth prospects,
strong business fundamentals
low financial leverage,
trading at an attractive valuation, and with some sort of short term difficulties that have caused the market perception to be negative in the short term.
To value companies I use a variety of techniques, sometimes heavily favoring traditional value metrics like P/B, and also I like good business (ROIC, ROE) trading at attractive multiples against EBITDA. I do discounted cash flow analysis where appropriate, and in some cases favor heavily on comparative valuation.
Jason is a small business owner that has been investing in stocks since 1989. He is a value/growth investor.
Jason holds degrees in biomedical engineering and materials engineering and from Rensselaer Polytechnic Institute and started his own company in 2001, thus increasing his enjoyment of life considerably.
Disclaimer: Jason reminds investors to always do their own due diligence on any investment, and to consult their own financial adviser or representative when necessary. Any material provided is intended as general information only, and should not be considered or relied upon as a formal investment recommendation.
Mike Havrilla is a former pharmacist (retail and home infusion settings), biotech stock trader, and writer with experience that includes online trading since 1997, working as a pharmacist during 2004-2014, and writing for investors since 2007. Mike holds Doctor of Pharmacy (PharmD) and Bachelor of Science (Biology) degrees from the University of Pittsburgh and worked in the pharmaceutical industry for Wyeth prior to pharmacy school. He is also an avid runner and has completed over 20 marathons with a personal best time under three hours for the 26.2 mile race and under 80 minutes for the half marathon. Mike merged his former publishing business with BioRunUp.com / Mark Messier in October 2010, creating a new online biotech stock research and trading subscription service.